# Ironwood Pharmaceuticals Inc: financial statements, quarterly

IRWD · Nasdaq · CIK 1446847 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/irwd.md) · [Financials](/companies/irwd/financials.md) · [Filings](/companies/irwd/filings.md) · [Insiders](/companies/irwd/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/irwd/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [114](/filings/0001558370-25-004072.md) | [118](/filings/0001558370-25-004072.md) | [74.9](/filings/0001104659-26-020489.md) | [94.4](/filings/0001104659-26-020489.md) | [91.6](/filings/0001104659-26-020489.md) | [90.5](/filings/0001104659-26-020489.md) | [41.1](/filings/0001104659-26-057110.md) | [85.2](/filings/0001104659-26-091987.md) | [122](/filings/0001104659-26-020489.md) | [47.7](/filings/0001104659-26-020489.md) | [107](/filings/0001104659-26-057110.md) | [113](/filings/0001104659-26-091987.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [33.0](/filings/0001558370-24-014909.md) | [35.7 d](/filings/0001558370-25-004072.md) | [25.8](/filings/0001558370-25-007406.md) | [30.4](/filings/0001558370-25-011050.md) | [29.8](/filings/0001104659-25-108795.md) | [25.4 d](/filings/0001104659-26-020489.md) | [27.4](/filings/0001104659-26-057110.md) | [23.4](/filings/0001104659-26-091987.md) | [22.5](/filings/0001104659-25-108795.md) | [21.9 d](/filings/0001104659-26-020489.md) | [21.9](/filings/0001104659-26-057110.md) | [22.4](/filings/0001104659-26-091987.md) |
| Selling, general and administrative | $m | [36.0](/filings/0001558370-24-014909.md) | [38.7 d](/filings/0001558370-25-004072.md) | [37.6](/filings/0001558370-25-007406.md) | [37.0](/filings/0001558370-25-011050.md) | [36.1](/filings/0001104659-25-108795.md) | [33.6 d](/filings/0001104659-26-020489.md) | [24.3](/filings/0001104659-26-057110.md) | [16.8](/filings/0001104659-26-091987.md) | [21.9](/filings/0001104659-25-108795.md) | [19.3 d](/filings/0001104659-26-020489.md) | [12.0](/filings/0001104659-26-057110.md) | [11.3](/filings/0001104659-26-091987.md) |
| Operating income | $m | [40.0](/filings/0001558370-24-014909.md) | [37.6 d](/filings/0001558370-25-004072.md) | [11.0](/filings/0001558370-25-007406.md) | [25.0](/filings/0001558370-25-011050.md) | [25.6](/filings/0001104659-25-108795.md) | [31.5 d](/filings/0001104659-26-020489.md) | [(29.1)](/filings/0001104659-26-057110.md) | [45.3](/filings/0001104659-26-091987.md) | [75.5](/filings/0001104659-25-108795.md) | [6.8 d](/filings/0001104659-26-020489.md) | [72.6](/filings/0001104659-26-057110.md) | [79.3](/filings/0001104659-26-091987.md) |
| Interest expense | $m | [9.8](/filings/0001558370-23-018589.md) | [8.4 d](/filings/0001558370-24-001275.md) | [7.2](/filings/0001558370-24-007640.md) | [7.5](/filings/0001558370-25-011050.md) | [9.4](/filings/0001104659-25-108795.md) | [8.9 d](/filings/0001104659-26-020489.md) | [8.1](/filings/0001104659-26-057110.md) | [8.4](/filings/0001104659-26-091987.md) | [8.4](/filings/0001104659-25-108795.md) | [7.9 d](/filings/0001104659-26-020489.md) | [9.1](/filings/0001104659-26-057110.md) | [7.2](/filings/0001104659-26-091987.md) |
| Income tax | $m | [18.0](/filings/0001558370-24-014909.md) | [32.1 d](/filings/0001558370-25-004072.md) | [9.1](/filings/0001558370-25-007406.md) | [19.7](/filings/0001558370-25-011050.md) | [13.7](/filings/0001104659-25-108795.md) | [21.7 d](/filings/0001104659-26-020489.md) | [1.1](/filings/0001104659-26-057110.md) | [14.2](/filings/0001104659-26-091987.md) | [27.9](/filings/0001104659-25-108795.md) | [2.7 d](/filings/0001104659-26-020489.md) | [24.4](/filings/0001104659-26-057110.md) | [22.4](/filings/0001104659-26-091987.md) |
| Net income | $m | [15.3](/filings/0001558370-25-004072.md) | [(1.1)](/filings/0001558370-25-004072.md) | [(4.2)](/filings/0001104659-26-020489.md) | [(0.9)](/filings/0001104659-26-020489.md) | [3.6](/filings/0001104659-26-020489.md) | [2.3](/filings/0001104659-26-020489.md) | [(37.4)](/filings/0001104659-26-057110.md) | [23.6](/filings/0001104659-26-091987.md) | [40.1](/filings/0001104659-26-020489.md) | [(2.3)](/filings/0001104659-26-020489.md) | [40.8](/filings/0001104659-26-057110.md) | [51.3](/filings/0001104659-26-091987.md) |
| Diluted EPS | $ per share | [0.09](/filings/0001558370-25-004072.md) | [(0.01)](/filings/0001558370-25-004072.md) | [(0.03)](/filings/0001104659-26-020489.md) | [(0.01)](/filings/0001104659-26-020489.md) | [0.02](/filings/0001104659-26-020489.md) | [0.01](/filings/0001104659-26-020489.md) | [(0.23)](/filings/0001104659-26-057110.md) | [0.14](/filings/0001104659-26-091987.md) | [0.23](/filings/0001104659-26-020489.md) | [(0.01)](/filings/0001104659-26-020489.md) | [0.24](/filings/0001104659-26-057110.md) | [0.31](/filings/0001104659-26-091987.md) |
| Basic EPS | $ per share | [0.10](/filings/0001558370-25-004072.md) | [(0.01)](/filings/0001558370-25-004072.md) | [(0.03)](/filings/0001104659-26-020489.md) | [(0.01)](/filings/0001104659-26-020489.md) | [0.02](/filings/0001104659-26-020489.md) | [0.01](/filings/0001104659-26-020489.md) | [(0.23)](/filings/0001104659-26-057110.md) | [0.15](/filings/0001104659-26-091987.md) | [0.25](/filings/0001104659-26-020489.md) | [(0.01)](/filings/0001104659-26-020489.md) | [0.25](/filings/0001104659-26-057110.md) | [0.31](/filings/0001104659-26-091987.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [110](/filings/0001558370-24-014909.md) | [92.2](/filings/0001558370-25-004072.md) | [122](/filings/0001558370-24-007640.md) | [106](/filings/0001558370-24-011590.md) | [88.2](/filings/0001558370-24-014909.md) | [88.6](/filings/0001104659-26-020489.md) | [108](/filings/0001558370-25-007406.md) | [92.9](/filings/0001558370-25-011050.md) | [140](/filings/0001104659-25-108795.md) | [215](/filings/0001104659-26-091987.md) | [220](/filings/0001104659-26-057110.md) | [79.1](/filings/0001104659-26-091987.md) |
| Current assets | $m | [254](/filings/0001558370-23-018589.md) | [233](/filings/0001558370-25-004072.md) | [208](/filings/0001558370-24-007640.md) | [178](/filings/0001558370-24-011590.md) | [179](/filings/0001558370-24-014909.md) | [182](/filings/0001104659-26-020489.md) | [161](/filings/0001558370-25-007406.md) | [192](/filings/0001558370-25-011050.md) | [274](/filings/0001104659-25-108795.md) | [274](/filings/0001104659-26-091987.md) | [332](/filings/0001104659-26-057110.md) | [199](/filings/0001104659-26-091987.md) |
| Total assets | $m | [524](/filings/0001558370-23-018589.md) | [471](/filings/0001558370-25-004072.md) | [439](/filings/0001558370-24-007640.md) | [396](/filings/0001558370-24-011590.md) | [390](/filings/0001558370-24-014909.md) | [351](/filings/0001104659-26-020489.md) | [327](/filings/0001558370-25-007406.md) | [343](/filings/0001558370-25-011050.md) | [396](/filings/0001104659-25-108795.md) | [397](/filings/0001104659-26-091987.md) | [435](/filings/0001104659-26-057110.md) | [285](/filings/0001104659-26-091987.md) |
| Current liabilities | $m | [281](/filings/0001558370-23-018589.md) | [276](/filings/0001558370-25-004072.md) | [252](/filings/0001558370-24-007640.md) | [45.5](/filings/0001558370-24-011590.md) | [49.4](/filings/0001558370-24-014909.md) | [38.8](/filings/0001104659-26-020489.md) | [48.1](/filings/0001558370-25-007406.md) | [233](/filings/0001558370-25-011050.md) | [243](/filings/0001104659-25-108795.md) | [242](/filings/0001104659-26-091987.md) | [236](/filings/0001104659-26-057110.md) | [32.9](/filings/0001104659-26-091987.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [659](/filings/0001104659-26-091987.md) | not reported | [447](/filings/0001104659-26-091987.md) |
| Long-term debt | $m | [397](/filings/0001558370-23-018589.md) | [398](/filings/0001558370-24-014909.md) | [398](/filings/0001558370-24-007640.md) | [199](/filings/0001558370-24-011590.md) | [199](/filings/0001558370-24-014909.md) | [199](/filings/0001104659-25-108795.md) | [199](/filings/0001558370-25-007406.md) | [199](/filings/0001558370-25-011050.md) | [200](/filings/0001104659-25-108795.md) | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(323)](/filings/0001558370-23-018589.md) | [(346)](/filings/0001558370-25-004072.md) | [(331)](/filings/0001558370-24-007640.md) | [(322)](/filings/0001558370-24-011590.md) | [(311)](/filings/0001558370-24-014909.md) | [(301)](/filings/0001104659-26-020489.md) | [(334)](/filings/0001558370-25-007406.md) | [(308)](/filings/0001558370-25-011050.md) | [(264)](/filings/0001104659-25-108795.md) | [(262)](/filings/0001104659-26-091987.md) | [(217)](/filings/0001104659-26-057110.md) | [(162)](/filings/0001104659-26-091987.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [32.5 d](/filings/0001558370-24-014909.md) | [35.8 d](/filings/0001558370-25-004072.md) | [45.0](/filings/0001558370-25-007406.md) | [33.5 d](/filings/0001558370-25-011050.md) | [9.9 d](/filings/0001104659-25-108795.md) | [15.2 d](/filings/0001104659-26-020489.md) | [20.0](/filings/0001104659-26-057110.md) | [(15.1) d](/filings/0001104659-26-091987.md) | [47.6 d](/filings/0001104659-25-108795.md) | [74.6 d](/filings/0001104659-26-020489.md) | [5.1](/filings/0001104659-26-057110.md) | [58.3 d](/filings/0001104659-26-091987.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-24-014909.md) | [0.2 d](/filings/0001558370-25-004072.md) | [0.1](/filings/0001558370-25-007406.md) | [0.1 d](/filings/0001558370-25-011050.md) | [0.0 d](/filings/0001104659-25-108795.md) | [0.0 d](/filings/0001104659-26-020489.md) | [0.0](/filings/0001104659-26-057110.md) | [0.0 d](/filings/0001104659-26-091987.md) | [0.0 d](/filings/0001104659-25-108795.md) | [(0.0) d](/filings/0001104659-26-020489.md) | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [184](/filings/0001558370-23-018589.md) | [187](/filings/0001558370-24-007640.md) | [155](/filings/0001558370-24-011590.md) | [187](/filings/0001558370-24-014909.md) | [158](/filings/0001558370-25-007406.md) | [159](/filings/0001558370-25-011050.md) | [160](/filings/0001104659-25-108795.md) | [161](/filings/0001104659-26-057110.md) | [177](/filings/0001104659-26-091987.md) | [178](/filings/0001104659-25-108795.md) | [167](/filings/0001104659-26-057110.md) | [167](/filings/0001104659-26-091987.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 165,239,947 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-091987.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.